Don't count Merck's Keytruda out in lung cancer fight with BMS' Opdivo

Those following the checkpoint inhibitor battle between Bristol-Myers Squibb's ($BMY) Opdivo and Merck's ($MRK) Keytruda--particularly in the lung cancer arena--know that industry watchers largely expect Opdivo to come out on top, sales-wise. But don't count out the Merck drug, even if it winds up with a narrower label, Bernstein analyst Tim Anderson wrote in a recent note to clients. "This near-term label decision may not matter as much as investors think," he said. More from FiercePharmaMarketing